Peptides AcademyGLP-1 Analog Peptides
Semaglutide, liraglutide, and related incretin-based peptides approved for glycemic control and chronic weight management.
GLP-1 Receptor Agonists (8)
Cagrilintide
Novo Nordisk
A long-acting amylin analog in development by Novo Nordisk, studied in combination with semaglutide (CagriSema) for obesity — achieving up to 24% weight loss in trials.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
Endogenous
A 42-amino-acid incretin hormone secreted by K-cells in the duodenum and jejunum that potentiates glucose-dependent insulin secretion and plays a central role in the mechanism of tirzepatide and retatrutide.
Liraglutide
Saxenda / Victoza
The first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014) — an acylated human GLP-1 analog with ~13-hour half-life dosed once daily.
Nesfatin-1
Research-Grade
An 82-amino-acid anorexigenic peptide derived from nucleobindin-2 (NUCB2) that suppresses appetite through hypothalamic signaling and crosses the blood-brain barrier, studied for potential anti-obesity applications.
Orforglipron
Eli Lilly
An oral, non-peptide GLP-1 receptor agonist in phase 3 development by Eli Lilly, representing a potential paradigm shift from injectable to oral incretin-based therapies for obesity and type 2 diabetes.
Pemvidutide
Altimmune (investigational)
A dual GLP-1/glucagon receptor agonist developed by Altimmune for MASH and obesity, designed to leverage glucagon-driven hepatic fat reduction alongside GLP-1-mediated appetite suppression.
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Survodutide
Boehringer Ingelheim (investigational)
A dual GLP-1/glucagon receptor agonist in phase 3 development by Boehringer Ingelheim for MASH (metabolic dysfunction-associated steatohepatitis) and obesity, with strong liver-directed efficacy signals.